These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8001709)

  • 1. [Preventive treatment of diabetic microangiopathy: blocking the pathogenic mechanisms].
    Guillausseau PJ
    Diabete Metab; 1994; 20(2 Pt 2):219-28. PubMed ID: 8001709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of long-term complications of non-insulin-dependent diabetes mellitus.
    Nathan DM
    Clin Invest Med; 1995 Aug; 18(4):332-9. PubMed ID: 8549021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microangiopathy in diabetes mellitus: I. Causes, prevention and treatment.
    Chittenden SJ; Shami SK
    Diabetes Res; 1991 Jul; 17(3):105-14. PubMed ID: 1841026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and vascular factors in the pathogenesis of diabetic neuropathy.
    Ward JD
    Clin Invest Med; 1995 Aug; 18(4):267-74. PubMed ID: 8549012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldose reductase and its inhibition in the control of diabetic complications.
    Narayanan S
    Ann Clin Lab Sci; 1993; 23(2):148-58. PubMed ID: 8457142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New concepts and insights on pathogenesis and treatment of diabetic complications: polyol pathway and its inhibition.
    Hotta N
    Nagoya J Med Sci; 1997 Nov; 60(3-4):89-100. PubMed ID: 9481088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications.
    Friedman EA
    Diabetes Care; 1999 Mar; 22 Suppl 2():B65-71. PubMed ID: 10097902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of polyol pathway in pathogenesis of diabetic microangiopathy].
    Nakamura J
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():52-61. PubMed ID: 15999685
    [No Abstract]   [Full Text] [Related]  

  • 10. [Microvascular complications in diabetes mellitus. Pathogenetic aspects].
    Andronico G; Cerasola G
    Minerva Endocrinol; 1992; 17(2):67-73. PubMed ID: 1296146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects for angiotensin receptor blockers in diabetic retinopathy.
    Sjølie AK
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S31-9. PubMed ID: 17321627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
    Sun W; Oates PJ; Coutcher JB; Gerhardinger C; Lorenzi M
    Diabetes; 2006 Oct; 55(10):2757-62. PubMed ID: 17003340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
    Yamagishi S; Takeuchi M; Inagaki Y; Nakamura K; Imaizumi T
    Int J Clin Pharmacol Res; 2003; 23(4):129-34. PubMed ID: 15224502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering?
    Leiter LA
    Diabetes Res Clin Pract; 2005 Jun; 68 Suppl 2():S3-14. PubMed ID: 15953505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological approach to diabetic retinopathy.
    De La Cruz JP; González-Correa JA; Guerrero A; de la Cuesta FS
    Diabetes Metab Res Rev; 2004; 20(2):91-113. PubMed ID: 15037985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of protein kinase C might be harmful to diabetic retinopathy.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2004; 63(1):135-7. PubMed ID: 15193366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic microangiopathy: physiopathological, clinical and therapeutic aspects.
    Camera A; Hopps E; Caimi G
    Minerva Endocrinol; 2007 Sep; 32(3):209-29. PubMed ID: 17912158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of microvascular and macrovascular complications in diabetes mellitus.
    Maji D
    J Indian Med Assoc; 2004 Aug; 102(8):426, 428, 430 passim. PubMed ID: 15719805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes.
    Cameron NE; Gibson TM; Nangle MR; Cotter MA
    Ann N Y Acad Sci; 2005 Jun; 1043():784-92. PubMed ID: 16037306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldose reductase in diabetic microvascular complications.
    Chung SS; Chung SK
    Curr Drug Targets; 2005 Jun; 6(4):475-86. PubMed ID: 16026266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.